Female scientist in lab

Chr. Hansen’s Lactobacillus rhamnosus, LGG®

The world’s most documented probiotic strain

Lactobacillus rhamnosus, LGG® (hereafter referred to by use of the trademark, LGG® ) is the world’s most documented probiotic strain. LGG® has been used worldwide since 1990 as an ingredient in food and dietary supplements with no safety issues.  

It has been extensively studied across various health areas, in newborns,1 preterm infants,2 children,3, 4, 5 pregnant women,6, 7 adults8 and in the elderly,9 with no safety issues.  

The LGG® strain has been described in more than 250 publications of human studies.  

 

High bile and acid tolerance 

Lab-based research has shown that the LGG® probiotic strain has high bile and acid tolerance, which may be important for a probiotic strain to survive passage through the gastrointestinal tract and for its potential beneficial effects. (Ref: Data from Chr. Hansen Human Health Development). 

The LGG® strain supports intestinal barrier function by helping intestinal integrity and supporting the immune system. (Ref: Data from Chr. Hansen Human Health Development).  

 

To view this content consent for functional cookies needs to be given. Click this text to open the consent form.

In children, some of the most researched health areas with the LGG® probiotic strain are:  

  • Loose and watery stools 
    LGG® has been associated with fewer instances1 and shorter episodes of loose and watery stools5, 10, 11 and normal bowel habits.3, 11  

  • Health conditions related to hospitalization  
    LGG® has been associated with fewer hospitalization-related digestive system issues4 and fewer respiratory tract discomfort that can occur following hospitalization.4 

  • Immune challenges related to respiratory health  
    LGG® has been associated with fewer respiratory challenges,4 , 12 fewer instances of respiratory challenges that last more than three days,4, 12 and significantly less days with signs of respiratory discomfort.11  

  • Oral health  
    Based on human studies and microbiological evaluation, LGG® has been associated with more healthy teeth,13 and with lower levels of specific bacteria that contributes to poor oral health.14  


In adults, some of the most researched health areas with the LGG® strain are:  

  • Travel-related loose stools  
    LGG® has been associated with a reduction in the incidence of loose stools that travelers commonly experience when traveling in countries, regions and areas which present more chance of being exposed to unfamiliar bacteria.8 

  • Immune health  
    LGG® probiotic supplementation has been associated with significantly higher levels of antibodies (natural proteins integral to immune system function), which suggests support for immune health.15  
 

To view this content consent for functional cookies needs to be given. Click this text to open the consent form.


Only Chr. Hansen can offer the real LGG® 

Chr. Hansen uses state-of-the-art sequencing to generate a closed genome reference sequence of the LGG® probiotic strain. The genome results and sequences have been validated and endorsed by an independent third party. The Valio and Chr. Hansen production strain has remained stable and genomically identical over the last 25 years. 

It was observed in 2019 that the ATCC reference deposit of LGG (ATCC53103) was not genomically identical to the Chr. Hansen LGG® production strain or the published LGG sequence.16 For this reason, the LGG® production strain from Chr. Hansen has been deposited at the DSMZ culture collection (DSM33156). 

 

  • LGG® from Chr. Hansen has had 100% genome stability for more than 25 years 
    The Chr. Hansen probiotic strain has remained stable and genomically identical over the last 25 years. 
  • The real LGG® by Chr. Hansen is the one used in over 75% of all publications based on human studies.
    Valio or Chr. Hansen supplied the LGG® strain to more than 75% of all publications based on human studies investigating Lactobacillus rhamnosus GG. This means that in less than 25% of the publications on human studies, the strain was supplied by another supplier or is unknown. 

  • The results and sequences are provided and endorsed by independent third parties.
    Results from our genome and sequence analysis have been validated and endorsed by an independent third party. 

  • The LGG® strain from Chr. Hansen is stable for up to three years at temperatures up to 30 degrees (zone 4b).


The LGG® probiotic strain is safe for human consumption and in Europe has been granted QPS (Qualified Presumption of Safety) status in Europe17 and been the subject of a GRAS (Generally Recognized As Safe) notice to the US Food and Drug Administration,18 with no safety issues. 


To view this content consent for functional cookies needs to be given. Click this text to open the consent form.


LGG® is a registered trademark of Chr. Hansen A/S.

 

Want to know more?

Male and female scientists in lab
Page

What are probiotics?
Four kids smiling
Page

What is the human microbiome?<br/>
Elderly man and boy with feet in water
Page

The Probiotic Powerhouse: science-based customized solutions for you
 

References

1 Arvola T, et al. Pediatrics. 1999;104(5):e64.
2 Underwood MA, et al. Journal of Pediatric Gastroenterology and Nutrition. 2009;48(2):216-25.
3 Vanderhoof JA, et al. The Journal of Pediatrics. 1999;135(5):564-8.
4 Hojsak I, et al. Pediatrics. 2010;125(5):e1171-7.
5 Isolauri E, et al. Pediatrics. 1991;88(1):90-7.
6 Gueimonde M, et al. Journal of Pediatric Gastroenterology and Nutrition. 2006;42(2):166-70.7. Lahtinen SJ, et al. J Allergy Clin Immunol. 2009;123(2):499-5019. Hatakka K, et al. J Dent Res. 2007;86(2):125-30.
10 Sindhu KNC, et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(8):1107-15.
11 Aggarwal S, et al. Indian J Med Res. 2014;139(3):379-85.
12 Hojsak I, et al. Clin Nutr. 2010;29(3):312-6.
13 Nase L, et al. Caries Res. 2001;35(6):412-20.
14 Glavina D, et al. Coll Antropol. 2012;36(1):129-32.
15 Davidson LE, et al. Eur J Clin Nutr. 2011;65(4):501-7.
16 Vos WM. 2009. Proc Natl Acad Sci United States Am 106:17193 –17198.
17 EFSA Panel on Biological Hazards (BIOHAZ). EFSA Journal. 2015;13:4331.
18 Food and Drug Administration. GRAS Notice No GRN 000049. 2002.

 

This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers of final consumer goods. Nothing on this page is meant to be perceived as an approved claim.

Share this with: